NEW YORK--(BUSINESS WIRE)--Lev Pharmaceuticals, Inc. (“Lev” or the “Company”) (OTCBB:LEVP.OB - News) today announced the submission of an amendment to its pending Biologics License Application (BLA) for Cinryze™ (C1 inhibitor) for the treatment of hereditary angioedema (HAE), also known as C1 inhibitor deficiency. The amendment includes the data from the Company’s pivotal U.S. Phase III trial of Cinryze™ for the prophylactic treatment of HAE.
